Neurotensin receptor 1 (NTSR1) targeted therapeutics and uses thereof
Radiopharmaceuticals targeting Neurotensin Receptor 1 (NTSR1) address the lack of specificity in current cancer treatments by delivering radionuclides to NTSR1-overexpressing tumors, offering effective cancer therapy and diagnosis with reduced side effects.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- RADIONETICS ONCOLOGY INC
- Filing Date
- 2025-11-19
- Publication Date
- 2026-05-28
AI Technical Summary
Current cancer treatments, such as chemotherapy and radiation therapy, lack specificity for malignant cells, leading to severe side effects due to non-selective targeting of healthy tissues, and there is a need for targeted delivery of radionuclides to tumors overexpressing Neurotensin Receptor 1 (NTSR1) for improved cancer therapy and diagnosis.
Development of radiopharmaceuticals that selectively target Neurotensin Receptor 1 (NTSR1)-overexpressing tumors using nonpeptide compounds with chelating moieties and radionuclide complexes for targeted delivery of radionuclides for cancer treatment and diagnosis.
The radiopharmaceuticals provide selective delivery of radionuclides to NTSR1-overexpressing tumors, enabling effective cancer treatment and diagnostic imaging with reduced side effects by specifically targeting malignant cells.
Smart Images
Figure US2025056104_28052026_PF_FP_ABST